Roche shared an update on the safety of RG7916.
NHS England has published an Interim Commissioning Policy on nusinersen EAP.
Dear Community, During the last few weeks NHSE and Biogen has been discussing the support for EAP. As we know, NHSE current official position is that they are not willing to fund additional auxiliary costs associated with Spinraza administration. Whilst Biogen expressed willingness to cooperate, pharmaceutical companies in general are not allowed to pay doctors…
Today a group of TreatSMA families attended a meeting of the All-Party Parliamentary Group for Muscular Dystrophy at the House of Lords.
First ever treatment for life-devastating condition is approved by European Commission!
On the 19th of May, Biogen attended a meeting arranged between 4 patient advocacy groups: Muscular Dystrophy UK, SMA Trust, SMA Support UK and TreatSMA.